128 related articles for article (PubMed ID: 23368732)
1. Cucurbitacins: potential candidates targeting mitogen-activated protein kinase pathway for treatment of melanoma.
Ahmed MS; Halaweish FT
J Enzyme Inhib Med Chem; 2014 Apr; 29(2):162-7. PubMed ID: 23368732
[TBL] [Abstract][Full Text] [Related]
2. Structural optimization and biological screening of a steroidal scaffold possessing cucurbitacin-like functionalities as B-Raf inhibitors.
Ahmed MS; Kopel LC; Halaweish FT
ChemMedChem; 2014 Jul; 9(7):1361-7. PubMed ID: 24682977
[TBL] [Abstract][Full Text] [Related]
3. Biological screening of cucurbitacin inspired estrone analogs targeting mitogen-activated protein kinase (MAPK) pathway.
Ahmed MS; El-Senduny F; Taylor J; Halaweish FT
Chem Biol Drug Des; 2017 Sep; 90(3):478-484. PubMed ID: 28171685
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
5. New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies.
Choi WK; El-Gamal MI; Choi HS; Baek D; Oh CH
Eur J Med Chem; 2011 Dec; 46(12):5754-62. PubMed ID: 22014559
[TBL] [Abstract][Full Text] [Related]
6. Cucurbitacin IIa interferes with EGFR-MAPK signaling pathway leads to proliferation inhibition in A549 cells.
Zhang J; Song Y; Liang Y; Zou H; Zuo P; Yan M; Jing S; Li T; Wang Y; Li D; Zhang T; Wei Z
Food Chem Toxicol; 2019 Oct; 132():110654. PubMed ID: 31265865
[TBL] [Abstract][Full Text] [Related]
7. Emerging Raf inhibitors.
McCubrey JA; Steelman LS; Abrams SL; Chappell WH; Russo S; Ove R; Milella M; Tafuri A; Lunghi P; Bonati A; Stivala F; Nicoletti F; Libra M; Martelli AM; Montalto G; Cervello M
Expert Opin Emerg Drugs; 2009 Dec; 14(4):633-48. PubMed ID: 19715444
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf.
Samadani R; Zhang J; Brophy A; Oashi T; Priyakumar UD; Raman EP; St John FJ; Jung KY; Fletcher S; Pozharski E; MacKerell AD; Shapiro P
Biochem J; 2015 May; 467(3):425-38. PubMed ID: 25695333
[TBL] [Abstract][Full Text] [Related]
10. Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.
Pulici M; Traquandi G; Marchionni C; Modugno M; Lupi R; Amboldi N; Casale E; Colombo N; Corti L; Fasolini M; Gasparri F; Pastori W; Scolaro A; Donati D; Felder E; Galvani A; Isacchi A; Pesenti E; Ciomei M
ChemMedChem; 2015 Feb; 10(2):276-95. PubMed ID: 25430902
[TBL] [Abstract][Full Text] [Related]
11. MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S; Flaherty KT
Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
[TBL] [Abstract][Full Text] [Related]
12. BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma.
Breunig C; Mueller BJ; Umansky L; Wahl K; Hoffmann K; Lehner F; Manns MP; Bantel H; Falk CS
Clin Cancer Res; 2014 May; 20(9):2410-23. PubMed ID: 24573550
[TBL] [Abstract][Full Text] [Related]
13. Targeting MAPK pathway in melanoma therapy.
Cheng Y; Zhang G; Li G
Cancer Metastasis Rev; 2013 Dec; 32(3-4):567-84. PubMed ID: 23584575
[TBL] [Abstract][Full Text] [Related]
14. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
Siwak DR; Shishodia S; Aggarwal BB; Kurzrock R
Cancer; 2005 Aug; 104(4):879-90. PubMed ID: 16007726
[TBL] [Abstract][Full Text] [Related]
15. Cucurbitacins inspired organic synthesis: Potential dual inhibitors targeting EGFR - MAPK pathway.
Mahnashi M; Elgazwi SM; Ahmed MS; Halaweish FT
Eur J Med Chem; 2019 Jul; 173():294-304. PubMed ID: 31022583
[TBL] [Abstract][Full Text] [Related]
16. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.
Jiang CC; Lai F; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
Clin Cancer Res; 2011 Feb; 17(4):721-30. PubMed ID: 21088259
[TBL] [Abstract][Full Text] [Related]
17. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.
Panka DJ; Atkins MB; Mier JW
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2371s-2375s. PubMed ID: 16609061
[TBL] [Abstract][Full Text] [Related]
18. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases.
Sharma A; Tran MA; Liang S; Sharma AK; Amin S; Smith CD; Dong C; Robertson GP
Cancer Res; 2006 Aug; 66(16):8200-9. PubMed ID: 16912199
[TBL] [Abstract][Full Text] [Related]
19. Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
Kim YK; Ahn SK; Lee M
Cancer Lett; 2012 Jul; 320(2):215-24. PubMed ID: 22425959
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of a new series of highly potent RAF kinase-inhibiting triarylpyrazole derivatives possessing antiproliferative activity against melanoma cells.
Khan MA; El-Gamal MI; Tarazi H; Choi HS; Oh CH
Future Med Chem; 2016 Dec; 8(18):2197-2211. PubMed ID: 27845592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
